NO781078L - 5-(4-(diarylmetyl)-1-piperazinylalkyl)benzimidazolderivater - Google Patents
5-(4-(diarylmetyl)-1-piperazinylalkyl)benzimidazolderivaterInfo
- Publication number
- NO781078L NO781078L NO781078A NO781078A NO781078L NO 781078 L NO781078 L NO 781078L NO 781078 A NO781078 A NO 781078A NO 781078 A NO781078 A NO 781078A NO 781078 L NO781078 L NO 781078L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- formula
- piperazinylmethyl
- diphenylmethyl
- compound
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title claims description 7
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 107
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 239000002253 acid Substances 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 50
- 238000006243 chemical reaction Methods 0.000 claims description 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 39
- -1 alkali metal cyanocyanate Chemical class 0.000 claims description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 238000007363 ring formation reaction Methods 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 23
- 150000002431 hydrogen Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 230000001387 anti-histamine Effects 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 239000000376 reactant Substances 0.000 claims description 7
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical class NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 6
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 150000001299 aldehydes Chemical class 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 150000004820 halides Chemical class 0.000 claims description 5
- 229910052751 metal Chemical class 0.000 claims description 5
- 239000002184 metal Chemical class 0.000 claims description 5
- OAQDLZSNKCWMDY-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methylbenzimidazol-2-amine Chemical compound C=1C=C2N(C)C(N)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 OAQDLZSNKCWMDY-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 230000003266 anti-allergic effect Effects 0.000 claims description 4
- 239000000924 antiasthmatic agent Substances 0.000 claims description 4
- 230000002140 halogenating effect Effects 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007868 Raney catalyst Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 3
- 230000001088 anti-asthma Effects 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
- 125000005059 halophenyl group Chemical group 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 3
- KKMSCNTZDCYNSC-UHFFFAOYSA-N 1-[(4-fluorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 KKMSCNTZDCYNSC-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical group COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- ZBKAXLRWIUXFRC-UHFFFAOYSA-N 4-[(4-benzhydrylpiperazin-1-yl)methyl]-1-n-methylbenzene-1,2-diamine Chemical compound C1=C(N)C(NC)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 ZBKAXLRWIUXFRC-UHFFFAOYSA-N 0.000 claims description 2
- FBSMOKMUUDYZDO-UHFFFAOYSA-N 4-[(4-benzhydrylpiperazin-1-yl)methyl]-1-n-propylbenzene-1,2-diamine Chemical compound C1=C(N)C(NCCC)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 FBSMOKMUUDYZDO-UHFFFAOYSA-N 0.000 claims description 2
- XSWNFQROSUDYLR-UHFFFAOYSA-N 5-(chloromethyl)-2-methyl-1-propylbenzimidazole Chemical compound ClCC1=CC=C2N(CCC)C(C)=NC2=C1 XSWNFQROSUDYLR-UHFFFAOYSA-N 0.000 claims description 2
- JLRQZGHJSRVMEE-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1,2-dimethylbenzimidazole Chemical compound C=1C=C2N(C)C(C)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 JLRQZGHJSRVMEE-UHFFFAOYSA-N 0.000 claims description 2
- CVBJSXJXUYWGOM-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-propylbenzimidazole Chemical compound C=1C=C2N(CCC)C=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 CVBJSXJXUYWGOM-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 claims description 2
- 230000006179 O-acylation Effects 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- 150000001266 acyl halides Chemical class 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 150000001555 benzenes Chemical class 0.000 claims description 2
- 238000006114 decarboxylation reaction Methods 0.000 claims description 2
- 238000005695 dehalogenation reaction Methods 0.000 claims description 2
- YGBFFMMKLWVKGU-UHFFFAOYSA-N ethyl butanimidate;hydrochloride Chemical compound [Cl-].CCCC(=[NH2+])OCC YGBFFMMKLWVKGU-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- HWXYYUZBQKVFMV-UHFFFAOYSA-N n-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methylbenzimidazol-2-yl]acetamide Chemical compound C=1C=C2N(C)C(NC(=O)C)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 HWXYYUZBQKVFMV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- AXNUJYHFQHQZBE-UHFFFAOYSA-N 3-methylbenzene-1,2-diamine Chemical compound CC1=CC=CC(N)=C1N AXNUJYHFQHQZBE-UHFFFAOYSA-N 0.000 claims 2
- 238000009795 derivation Methods 0.000 claims 2
- VQLPOIFVOSNNKO-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-ethyl-2-methylbenzimidazole Chemical compound C=1C=C2N(CC)C(C)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 VQLPOIFVOSNNKO-UHFFFAOYSA-N 0.000 claims 1
- PLIIYELREAPEPA-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-ethyl-2-phenylbenzimidazole Chemical compound C=1C=C2N(CC)C(C=3C=CC=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 PLIIYELREAPEPA-UHFFFAOYSA-N 0.000 claims 1
- GVGLZMMKVQGJOC-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methyl-2-phenylbenzimidazole Chemical compound C=1C=C2N(C)C(C=3C=CC=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 GVGLZMMKVQGJOC-UHFFFAOYSA-N 0.000 claims 1
- AFIGUTZWZNFEMU-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-pentylbenzimidazole Chemical compound C=1C=C2N(CCCCC)C=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 AFIGUTZWZNFEMU-UHFFFAOYSA-N 0.000 claims 1
- CZTSLYOHYLWWIP-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-(4-fluorophenyl)-1-methylbenzimidazole Chemical compound C=1C=C2N(C)C(C=3C=CC(F)=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 CZTSLYOHYLWWIP-UHFFFAOYSA-N 0.000 claims 1
- AKZRGDYUJJORND-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-butyl-1-methylbenzimidazole Chemical compound C=1C=C2N(C)C(CCCC)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 AKZRGDYUJJORND-UHFFFAOYSA-N 0.000 claims 1
- HZPIHLNXDMOXSD-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-methyl-1-propylbenzimidazole Chemical compound C=1C=C2N(CCC)C(C)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 HZPIHLNXDMOXSD-UHFFFAOYSA-N 0.000 claims 1
- AAKSUAHVSGLJOW-UHFFFAOYSA-N 5-[[4-[(4-fluorophenyl)-phenylmethyl]piperazin-1-yl]methyl]-2-methyl-1-propylbenzimidazole Chemical compound C=1C=C2N(CCC)C(C)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC(F)=CC=1)C1=CC=CC=C1 AAKSUAHVSGLJOW-UHFFFAOYSA-N 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- ARUJJNVNLJPSDO-UHFFFAOYSA-N butanamide;hydrochloride Chemical compound Cl.CCCC(N)=O ARUJJNVNLJPSDO-UHFFFAOYSA-N 0.000 claims 1
- 238000006356 dehydrogenation reaction Methods 0.000 claims 1
- 230000026030 halogenation Effects 0.000 claims 1
- 238000005658 halogenation reaction Methods 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims 1
- 238000002844 melting Methods 0.000 description 75
- 230000008018 melting Effects 0.000 description 75
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 57
- 239000000047 product Substances 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 29
- 229960001701 chloroform Drugs 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 28
- 239000003480 eluent Substances 0.000 description 28
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 20
- 239000000284 extract Substances 0.000 description 20
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 12
- 239000000908 ammonium hydroxide Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229960001340 histamine Drugs 0.000 description 10
- 239000007858 starting material Substances 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000012258 stirred mixture Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HMVJXTUUQJUYJI-UHFFFAOYSA-N (3,4-diaminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1N HMVJXTUUQJUYJI-UHFFFAOYSA-N 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 5
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 230000036783 anaphylactic response Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 230000002804 anti-anaphylactic effect Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- FWOQZRBKEYHZRI-UHFFFAOYSA-N (2-propyl-3h-benzimidazol-5-yl)methanol Chemical compound OCC1=CC=C2NC(CCC)=NC2=C1 FWOQZRBKEYHZRI-UHFFFAOYSA-N 0.000 description 2
- OGFAWKRXZLGJSK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1=CC=C([N+]([O-])=O)C=C1 OGFAWKRXZLGJSK-UHFFFAOYSA-N 0.000 description 2
- MIXAIPZEDYTJIB-UHFFFAOYSA-N 1-benzhydryl-4-[(4-chloro-3-nitrophenyl)methyl]piperazine Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 MIXAIPZEDYTJIB-UHFFFAOYSA-N 0.000 description 2
- NWDCIQHALIFWCA-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(CCl)=CC=C1Cl NWDCIQHALIFWCA-UHFFFAOYSA-N 0.000 description 2
- IOXYSIVUDIRFFK-UHFFFAOYSA-N 2-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-phenylbenzimidazol-1-yl]ethanol Chemical compound C=1C=C2N(CCO)C(C=3C=CC=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 IOXYSIVUDIRFFK-UHFFFAOYSA-N 0.000 description 2
- FXNQTMRPLLNPQY-UHFFFAOYSA-N 2-bromo-1-(4-chloro-3-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC(C(=O)CBr)=CC=C1Cl FXNQTMRPLLNPQY-UHFFFAOYSA-N 0.000 description 2
- RGUHYIHANQYMAP-UHFFFAOYSA-N 2-methyl-1-propylbenzimidazole-5-carbonyl chloride;hydrochloride Chemical compound Cl.ClC(=O)C1=CC=C2N(CCC)C(C)=NC2=C1 RGUHYIHANQYMAP-UHFFFAOYSA-N 0.000 description 2
- LRHJEZOOBANSGC-UHFFFAOYSA-N 2-methyl-1-propylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(CCC)C(C)=NC2=C1 LRHJEZOOBANSGC-UHFFFAOYSA-N 0.000 description 2
- NCCPBFIZFBAPTB-UHFFFAOYSA-N 3-amino-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1N NCCPBFIZFBAPTB-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 2
- WWXFIBXWRNTLTE-UHFFFAOYSA-N 4-[(4-benzhydrylpiperazin-1-yl)methyl]-n-methyl-2-nitroaniline Chemical compound C1=C([N+]([O-])=O)C(NC)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 WWXFIBXWRNTLTE-UHFFFAOYSA-N 0.000 description 2
- IIOCECYTBZBBAL-UHFFFAOYSA-N 4-amino-3-nitrobenzaldehyde Chemical compound NC1=CC=C(C=O)C=C1[N+]([O-])=O IIOCECYTBZBBAL-UHFFFAOYSA-N 0.000 description 2
- BOJWTAQWPVBIPG-UHFFFAOYSA-N 4-fluoro-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 BOJWTAQWPVBIPG-UHFFFAOYSA-N 0.000 description 2
- CODGVZUONOKSOH-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-(2-chloroethyl)-2-phenylbenzimidazole Chemical compound C=1C=C2N(CCCl)C(C=3C=CC=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 CODGVZUONOKSOH-UHFFFAOYSA-N 0.000 description 2
- RPLMAYAFAKIEKK-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-(2-chloroethyl)benzimidazole Chemical compound C=1C=C2N(CCCl)C=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 RPLMAYAFAKIEKK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000004645 aluminates Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical class C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical compound OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- HLCUMQMYJXGGGN-UHFFFAOYSA-N methyl 2-methyl-1-propylbenzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(CCC)C(C)=NC2=C1 HLCUMQMYJXGGGN-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- ONLYDBPPTDIMGT-UHFFFAOYSA-N (2-cyclopropyl-3h-benzimidazol-5-yl)methanol Chemical compound N=1C2=CC(CO)=CC=C2NC=1C1CC1 ONLYDBPPTDIMGT-UHFFFAOYSA-N 0.000 description 1
- YEPJYHGFDCVBIU-UHFFFAOYSA-N (2-ethyl-3h-benzimidazol-5-yl)methanol Chemical compound OCC1=CC=C2NC(CC)=NC2=C1 YEPJYHGFDCVBIU-UHFFFAOYSA-N 0.000 description 1
- WSDNERLTMLWBGI-UHFFFAOYSA-N (2-methyl-1-propylbenzimidazol-5-yl)methanol Chemical compound OCC1=CC=C2N(CCC)C(C)=NC2=C1 WSDNERLTMLWBGI-UHFFFAOYSA-N 0.000 description 1
- WSLCWHXHFIDELG-UHFFFAOYSA-N (2-methyl-1-propylbenzimidazol-5-yl)methanol;hydrochloride Chemical compound Cl.OCC1=CC=C2N(CCC)C(C)=NC2=C1 WSLCWHXHFIDELG-UHFFFAOYSA-N 0.000 description 1
- GQAZGZORLFAOMV-UHFFFAOYSA-N (2-methyl-3h-benzimidazol-5-yl)methanol;hydrochloride Chemical compound Cl.OCC1=CC=C2NC(C)=NC2=C1 GQAZGZORLFAOMV-UHFFFAOYSA-N 0.000 description 1
- MNPFJZPAUPUXAQ-UHFFFAOYSA-N (2-phenyl-3h-benzimidazol-5-yl)methanol;hydrochloride Chemical compound Cl.N=1C2=CC(CO)=CC=C2NC=1C1=CC=CC=C1 MNPFJZPAUPUXAQ-UHFFFAOYSA-N 0.000 description 1
- ILPPPHYIRQHZOH-UHFFFAOYSA-N (2-propan-2-yl-3h-benzimidazol-5-yl)methanol Chemical compound OCC1=CC=C2NC(C(C)C)=NC2=C1 ILPPPHYIRQHZOH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CSWZPXTUXUWMSF-UHFFFAOYSA-N 1-[3-amino-4-(propylamino)phenyl]-2-(4-benzhydrylpiperazin-1-yl)ethanol Chemical compound C1=C(N)C(NCCC)=CC=C1C(O)CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 CSWZPXTUXUWMSF-UHFFFAOYSA-N 0.000 description 1
- KXHYVAOYKAPMLY-UHFFFAOYSA-N 1-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methylbenzimidazol-2-yl]-3-butylurea Chemical compound C=1C=C2N(C)C(NC(=O)NCCCC)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 KXHYVAOYKAPMLY-UHFFFAOYSA-N 0.000 description 1
- QIOWTPMFZYKNDX-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(4-chloro-3-nitrophenyl)methyl]piperazine Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(CN2CCN(CC2)C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)=C1 QIOWTPMFZYKNDX-UHFFFAOYSA-N 0.000 description 1
- TTZCSVBJJHMGJL-UHFFFAOYSA-N 1-benzhydryl-4-[(4-methoxy-3-nitrophenyl)methyl]piperazine;dihydrochloride Chemical compound Cl.Cl.C1=C([N+]([O-])=O)C(OC)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 TTZCSVBJJHMGJL-UHFFFAOYSA-N 0.000 description 1
- KPADRXLKVPDUGD-UHFFFAOYSA-N 1-benzhydryl-4-[(4-methoxy-3-nitrophenyl)methyl]piperazine;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1=C([N+]([O-])=O)C(OC)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 KPADRXLKVPDUGD-UHFFFAOYSA-N 0.000 description 1
- WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- SNHTVBUDFAHPND-UHFFFAOYSA-N 1h-benzimidazole;methanol Chemical compound OC.C1=CC=C2NC=NC2=C1 SNHTVBUDFAHPND-UHFFFAOYSA-N 0.000 description 1
- ODLKDTDUHORIOX-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-(1,2-dipropylbenzimidazol-5-yl)ethanol;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CCC)C(CCC)=NC2=CC=1C(O)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 ODLKDTDUHORIOX-UHFFFAOYSA-N 0.000 description 1
- AZHCVMPNHZRRFK-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-(1-ethyl-2-methylbenzimidazol-5-yl)ethanol Chemical compound C=1C=C2N(CC)C(C)=NC2=CC=1C(O)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 AZHCVMPNHZRRFK-UHFFFAOYSA-N 0.000 description 1
- RYOLQKVDXPGSAE-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-(1-ethyl-2-methylbenzimidazol-5-yl)ethanol;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CC)C(C)=NC2=CC=1C(O)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 RYOLQKVDXPGSAE-UHFFFAOYSA-N 0.000 description 1
- GDGZIKKVIGMLSH-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-(2-ethyl-1-propylbenzimidazol-5-yl)ethanol Chemical compound C=1C=C2N(CCC)C(CC)=NC2=CC=1C(O)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 GDGZIKKVIGMLSH-UHFFFAOYSA-N 0.000 description 1
- CPAKAJRWUPJEOU-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-(2-methyl-1-propylbenzimidazol-5-yl)ethanol Chemical compound C=1C=C2N(CCC)C(C)=NC2=CC=1C(O)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 CPAKAJRWUPJEOU-UHFFFAOYSA-N 0.000 description 1
- RBIOOFXBDYOQOL-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-(4-chloro-3-nitrophenyl)ethanone;dihydrochloride Chemical compound Cl.Cl.C1=C(Cl)C([N+](=O)[O-])=CC(C(=O)CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 RBIOOFXBDYOQOL-UHFFFAOYSA-N 0.000 description 1
- OPBDZICVSXNXJC-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-[3-nitro-4-(propylamino)phenyl]ethanol Chemical compound C1=C([N+]([O-])=O)C(NCCC)=CC=C1C(O)CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 OPBDZICVSXNXJC-UHFFFAOYSA-N 0.000 description 1
- YTJOKXXVQKICPR-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-yl)-1-[4-(ethylamino)-3-nitrophenyl]ethanol Chemical compound C1=C([N+]([O-])=O)C(NCC)=CC=C1C(O)CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 YTJOKXXVQKICPR-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- KJAKXLLHZFKFAW-UHFFFAOYSA-N 2-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-methylbenzimidazol-1-yl]ethanol Chemical compound C=1C=C2N(CCO)C(C)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 KJAKXLLHZFKFAW-UHFFFAOYSA-N 0.000 description 1
- KGSHBUOPBKUSBP-UHFFFAOYSA-N 2-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-methylbenzimidazol-1-yl]ethyl acetate Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)CC1=CC2=C(N(C(=N2)C)CCOC(C)=O)C=C1)C1=CC=CC=C1 KGSHBUOPBKUSBP-UHFFFAOYSA-N 0.000 description 1
- OEUOBTBUJXCJOC-UHFFFAOYSA-N 2-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-methylbenzimidazol-1-yl]ethyl methanesulfonate Chemical compound C=1C=C2N(CCOS(C)(=O)=O)C(C)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 OEUOBTBUJXCJOC-UHFFFAOYSA-N 0.000 description 1
- FKUZSCHUCHZNTG-UHFFFAOYSA-N 2-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-phenylbenzimidazol-1-yl]ethyl acetate Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)CC1=CC2=C(N(C(=N2)C2=CC=CC=C2)CCOC(C)=O)C=C1)C1=CC=CC=C1 FKUZSCHUCHZNTG-UHFFFAOYSA-N 0.000 description 1
- WVKBBARYEWPYJE-UHFFFAOYSA-N 2-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-phenylbenzimidazol-1-yl]ethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCCN(C1=CC=2)C(C=3C=CC=CC=3)=NC1=CC=2CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 WVKBBARYEWPYJE-UHFFFAOYSA-N 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- VNNQQIBJEKXVMZ-UHFFFAOYSA-N 3-[2-amino-4-[(4-benzhydrylpiperazin-1-yl)methyl]anilino]propan-1-ol Chemical compound C1=C(NCCCO)C(N)=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 VNNQQIBJEKXVMZ-UHFFFAOYSA-N 0.000 description 1
- XPPGFQGZZURBHX-UHFFFAOYSA-N 3-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-phenylbenzimidazol-1-yl]propyl acetate Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)CC1=CC2=C(N(C(=N2)C2=CC=CC=C2)CCCOC(C)=O)C=C1)C1=CC=CC=C1 XPPGFQGZZURBHX-UHFFFAOYSA-N 0.000 description 1
- DKRYRFRNGLTDMB-UHFFFAOYSA-N 4-(chloromethyl)-1-methoxy-2-nitrobenzene Chemical compound COC1=CC=C(CCl)C=C1[N+]([O-])=O DKRYRFRNGLTDMB-UHFFFAOYSA-N 0.000 description 1
- BCBDBIPRQQOXIF-UHFFFAOYSA-N 4-[(4-benzhydrylpiperazin-1-yl)methyl]-1-N-butylbenzene-1,2-diamine Chemical compound C1=C(N)C(NCCCC)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 BCBDBIPRQQOXIF-UHFFFAOYSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- CPWXRDWLNFCMCB-UHFFFAOYSA-N 5-(chloromethyl)-1-ethyl-2-phenylbenzimidazole;hydrochloride Chemical compound Cl.N=1C2=CC(CCl)=CC=C2N(CC)C=1C1=CC=CC=C1 CPWXRDWLNFCMCB-UHFFFAOYSA-N 0.000 description 1
- KEIBUMFMSMILIF-UHFFFAOYSA-N 5-(chloromethyl)-2-methyl-1-propylbenzimidazole;hydrochloride Chemical compound Cl.ClCC1=CC=C2N(CCC)C(C)=NC2=C1 KEIBUMFMSMILIF-UHFFFAOYSA-N 0.000 description 1
- QJISSFYEIKCAIM-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-(2-phenylsulfanylethyl)benzimidazole Chemical compound C=1C=CC=CC=1SCCN(C1=CC=2)C=NC1=CC=2CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 QJISSFYEIKCAIM-UHFFFAOYSA-N 0.000 description 1
- MBOAPPZZTQTYIA-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-ethylbenzimidazol-2-amine Chemical compound C=1C=C2N(CC)C(N)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 MBOAPPZZTQTYIA-UHFFFAOYSA-N 0.000 description 1
- BPLZBIFNQXUOBP-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-ethylbenzimidazole Chemical compound C=1C=C2N(CC)C=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BPLZBIFNQXUOBP-UHFFFAOYSA-N 0.000 description 1
- AFYYCSXVJTVQEY-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methyl-2-(2-methylphenyl)benzimidazole Chemical compound CC1=CC=CC=C1C1=NC2=CC(CN3CCN(CC3)C(C=3C=CC=CC=3)C=3C=CC=CC=3)=CC=C2N1C AFYYCSXVJTVQEY-UHFFFAOYSA-N 0.000 description 1
- ZMFUSQBJNJNREI-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methyl-2-pyridin-4-ylbenzimidazole Chemical compound C=1C=C2N(C)C(C=3C=CN=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 ZMFUSQBJNJNREI-UHFFFAOYSA-N 0.000 description 1
- UNWMHFPQFVAUCC-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-(2-chlorophenyl)-1-methylbenzimidazole Chemical compound C=1C=C2N(C)C(C=3C(=CC=CC=3)Cl)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UNWMHFPQFVAUCC-UHFFFAOYSA-N 0.000 description 1
- SGUGFVDYKOITDQ-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-(3-chlorophenyl)-1-methylbenzimidazole Chemical compound C=1C=C2N(C)C(C=3C=C(Cl)C=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 SGUGFVDYKOITDQ-UHFFFAOYSA-N 0.000 description 1
- PMSAMZRXMQUCRD-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-(4-chlorophenyl)-1-methylbenzimidazole Chemical compound C=1C=C2N(C)C(C=3C=CC(Cl)=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 PMSAMZRXMQUCRD-UHFFFAOYSA-N 0.000 description 1
- SNSPCWBVSDNQNB-UHFFFAOYSA-N 5-[(4-benzhydrylpiperazin-1-yl)methyl]-2-(furan-2-yl)-1-methylbenzimidazole Chemical compound C=1C=C2N(C)C(C=3OC=CC=3)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 SNSPCWBVSDNQNB-UHFFFAOYSA-N 0.000 description 1
- BUQCKSUBRJERCX-UHFFFAOYSA-N 5-[2-(4-benzhydrylpiperazin-1-yl)-1-chloroethyl]-1,2-dipropylbenzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CCC)C(CCC)=NC2=CC=1C(Cl)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BUQCKSUBRJERCX-UHFFFAOYSA-N 0.000 description 1
- ANHFXGASUNWTAT-UHFFFAOYSA-N 5-[2-(4-benzhydrylpiperazin-1-yl)-1-chloroethyl]-1-ethyl-2-methylbenzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CC)C(C)=NC2=CC=1C(Cl)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 ANHFXGASUNWTAT-UHFFFAOYSA-N 0.000 description 1
- DXZOONHHVOHQKN-UHFFFAOYSA-N 5-[2-(4-benzhydrylpiperazin-1-yl)-1-chloroethyl]-2-ethyl-1-propylbenzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CCC)C(CC)=NC2=CC=1C(Cl)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 DXZOONHHVOHQKN-UHFFFAOYSA-N 0.000 description 1
- FCTYUJBXVFPDSW-UHFFFAOYSA-N 5-[2-(4-benzhydrylpiperazin-1-yl)-1-chloroethyl]-2-methyl-1-propylbenzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CCC)C(C)=NC2=CC=1C(Cl)CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 FCTYUJBXVFPDSW-UHFFFAOYSA-N 0.000 description 1
- BFIKMERLJYJBSB-UHFFFAOYSA-N 5-[2-(4-benzhydrylpiperazin-1-yl)ethyl]-1,2-dipropylbenzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CCC)C(CCC)=NC2=CC=1CCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BFIKMERLJYJBSB-UHFFFAOYSA-N 0.000 description 1
- BOCKKEXFEQSYOT-UHFFFAOYSA-N 5-[2-(4-benzhydrylpiperazin-1-yl)ethyl]-2-ethyl-1-propylbenzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C2N(CCC)C(CC)=NC2=CC=1CCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BOCKKEXFEQSYOT-UHFFFAOYSA-N 0.000 description 1
- AYZCQMHQFIHZQH-UHFFFAOYSA-N 5-[2-(4-benzhydrylpiperazin-1-yl)ethyl]-2-methyl-1-propylbenzimidazole Chemical compound C=1C=C2N(CCC)C(C)=NC2=CC=1CCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 AYZCQMHQFIHZQH-UHFFFAOYSA-N 0.000 description 1
- ZJQCVDIETSAIOG-UHFFFAOYSA-N 5-[[4-[(4-fluorophenyl)-phenylmethyl]piperazin-1-yl]methyl]-1-methylbenzimidazol-2-amine Chemical compound C=1C=C2N(C)C(N)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC(F)=CC=1)C1=CC=CC=C1 ZJQCVDIETSAIOG-UHFFFAOYSA-N 0.000 description 1
- SISRPUDKUQDDNA-UHFFFAOYSA-N 5-[[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-1-methylbenzimidazol-2-amine Chemical compound C=1C=C2N(C)C(N)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 SISRPUDKUQDDNA-UHFFFAOYSA-N 0.000 description 1
- VCTCIVAXIRANKA-UHFFFAOYSA-N 6-(chloromethyl)-2-propyl-1h-benzimidazole;hydrochloride Chemical compound Cl.ClCC1=CC=C2NC(CCC)=NC2=C1 VCTCIVAXIRANKA-UHFFFAOYSA-N 0.000 description 1
- IPNCLTHNJNMLEB-UHFFFAOYSA-N 6-[(4-benzhydrylpiperazin-1-yl)methyl]-3-ethyl-1h-benzimidazol-2-one Chemical compound C1=C2NC(=O)N(CC)C2=CC=C1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 IPNCLTHNJNMLEB-UHFFFAOYSA-N 0.000 description 1
- LAXVGSAXSPXVJS-UHFFFAOYSA-N 6-[(4-benzhydrylpiperazin-1-yl)methyl]-3-methyl-1h-benzimidazol-2-one Chemical compound C1=C2NC(=O)N(C)C2=CC=C1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 LAXVGSAXSPXVJS-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- NKTYXKGAGBQXNM-UHFFFAOYSA-N C(C)(=O)OCC1=NC2=C(N1C(C)C)C=CC(=C2)CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=CC=C2 Chemical compound C(C)(=O)OCC1=NC2=C(N1C(C)C)C=CC(=C2)CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=CC=C2 NKTYXKGAGBQXNM-UHFFFAOYSA-N 0.000 description 1
- DFNRQNJAHLDLPJ-UHFFFAOYSA-N C(C)(=O)OCC1=NC2=C(N1CC)C=CC(=C2)CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=CC=C2 Chemical compound C(C)(=O)OCC1=NC2=C(N1CC)C=CC(=C2)CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=CC=C2 DFNRQNJAHLDLPJ-UHFFFAOYSA-N 0.000 description 1
- GZWCDIIIQJYHQH-UHFFFAOYSA-N C(C)(=O)OCC1=NC2=C(N1CCC)C=CC(=C2)CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=CC=C2 Chemical compound C(C)(=O)OCC1=NC2=C(N1CCC)C=CC(=C2)CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=CC=C2 GZWCDIIIQJYHQH-UHFFFAOYSA-N 0.000 description 1
- YZZOBOIKAOEZEH-UHFFFAOYSA-N C1(=CC=CC=C1)C(N1CCN(CC1)CC1=CC2=C(N(C(=N2)C)CCCOC(C)=O)C=C1)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)CC1=CC2=C(N(C(=N2)C)CCCOC(C)=O)C=C1)C1=CC=CC=C1 YZZOBOIKAOEZEH-UHFFFAOYSA-N 0.000 description 1
- JMGJJHBPTVTEEJ-UHFFFAOYSA-N C1(CC1)N1C(=NC2=C1C=CC(=C2)CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)COC(C)=O Chemical compound C1(CC1)N1C(=NC2=C1C=CC(=C2)CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)COC(C)=O JMGJJHBPTVTEEJ-UHFFFAOYSA-N 0.000 description 1
- YVLLCGAVHWZKLW-UHFFFAOYSA-N C1(CCCC1)N1C(=NC2=C1C=CC(=C2)CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)COC(C)=O Chemical compound C1(CCCC1)N1C(=NC2=C1C=CC(=C2)CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)COC(C)=O YVLLCGAVHWZKLW-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- SDWKBLZYFCUFOK-UHFFFAOYSA-N Cl.CCON=CCOC(=O)C1=CC=CC=C1 Chemical compound Cl.CCON=CCOC(=O)C1=CC=CC=C1 SDWKBLZYFCUFOK-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- NLNGZDGJYDKUSX-UHFFFAOYSA-N [5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-(2-methylpropyl)benzimidazol-2-yl]methyl acetate Chemical compound C(C)(=O)OCC1=NC2=C(N1CC(C)C)C=CC(=C2)CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1 NLNGZDGJYDKUSX-UHFFFAOYSA-N 0.000 description 1
- SMQPWRPTDQWLHP-UHFFFAOYSA-N [5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-butylbenzimidazol-2-yl]methyl acetate Chemical compound CCCCn1c(COC(C)=O)nc2cc(CN3CCN(CC3)C(c3ccccc3)c3ccccc3)ccc12 SMQPWRPTDQWLHP-UHFFFAOYSA-N 0.000 description 1
- PLIHPKDYFLVYCZ-UHFFFAOYSA-N [5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methylbenzimidazol-2-yl]methanol Chemical compound C=1C=C2N(C)C(CO)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 PLIHPKDYFLVYCZ-UHFFFAOYSA-N 0.000 description 1
- BKYMLQHPOYWCTO-UHFFFAOYSA-N [5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-methylbenzimidazol-2-yl]methyl acetate Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)CC1=CC2=C(N(C(=N2)COC(C)=O)C)C=C1)C1=CC=CC=C1 BKYMLQHPOYWCTO-UHFFFAOYSA-N 0.000 description 1
- CZZJHLIXLUGPPU-UHFFFAOYSA-N [5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-pentylbenzimidazol-2-yl]methyl acetate Chemical compound C1(=CC=CC=C1)C(N1CCN(CC1)CC1=CC2=C(N(C(=N2)COC(C)=O)CCCCC)C=C1)C1=CC=CC=C1 CZZJHLIXLUGPPU-UHFFFAOYSA-N 0.000 description 1
- RTBJAUXORAJUGI-UHFFFAOYSA-N [6-[(4-benzhydrylpiperazin-1-yl)methyl]-1h-benzimidazol-2-yl]methanol Chemical compound C=1C=C2NC(CO)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 RTBJAUXORAJUGI-UHFFFAOYSA-N 0.000 description 1
- UIRJMLYVMIMJSN-UHFFFAOYSA-N [6-[(4-benzhydrylpiperazin-1-yl)methyl]-1h-benzimidazol-2-yl]methyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC(NC1=C2)=NC1=CC=C2CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UIRJMLYVMIMJSN-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-M carbamimidothioate Chemical compound NC([S-])=N UMGDCJDMYOKAJW-UHFFFAOYSA-M 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 150000001912 cyanamides Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- 229910001511 metal iodide Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- NTEHWJBQADMGCG-UHFFFAOYSA-N n,n-dimethylformamide;nitrobenzene Chemical compound CN(C)C=O.[O-][N+](=O)C1=CC=CC=C1 NTEHWJBQADMGCG-UHFFFAOYSA-N 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- UTSWOJZNDWBSRH-UHFFFAOYSA-N n-[5-[(4-benzhydrylpiperazin-1-yl)methyl]-1-ethylbenzimidazol-2-yl]acetamide Chemical compound C=1C=C2N(CC)C(NC(C)=O)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UTSWOJZNDWBSRH-UHFFFAOYSA-N 0.000 description 1
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78265177A | 1977-03-30 | 1977-03-30 | |
US05/866,882 US4179505A (en) | 1977-03-30 | 1978-01-04 | 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NO781078L true NO781078L (no) | 1978-10-03 |
Family
ID=27120026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO781078A NO781078L (no) | 1977-03-30 | 1978-03-29 | 5-(4-(diarylmetyl)-1-piperazinylalkyl)benzimidazolderivater |
Country Status (25)
Country | Link |
---|---|
US (1) | US4179505A (el) |
JP (1) | JPS53141287A (el) |
AT (1) | AT368136B (el) |
AU (1) | AU517661B2 (el) |
CA (1) | CA1119597A (el) |
DE (1) | DE2813523A1 (el) |
DK (1) | DK135878A (el) |
ES (1) | ES468077A1 (el) |
FI (1) | FI780954A (el) |
FR (1) | FR2385713A1 (el) |
GB (1) | GB1598278A (el) |
GR (1) | GR66124B (el) |
HU (1) | HU180477B (el) |
IE (1) | IE46507B1 (el) |
IL (1) | IL54373A (el) |
IT (1) | IT1103464B (el) |
LU (1) | LU79326A1 (el) |
NL (1) | NL7803312A (el) |
NO (1) | NO781078L (el) |
NZ (1) | NZ186836A (el) |
PH (1) | PH16204A (el) |
PL (1) | PL118310B1 (el) |
PT (1) | PT67855B (el) |
SE (1) | SE7803057L (el) |
SU (1) | SU986297A3 (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4243806A (en) * | 1979-06-13 | 1981-01-06 | Janssen Pharmaceutica N.V. | 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives |
EP0034116A3 (en) * | 1980-02-11 | 1981-09-02 | Berlex Laboratories, Inc. | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines |
CH653021A5 (fr) * | 1981-04-24 | 1985-12-13 | Delalande Sa | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. |
JPS59118765A (ja) * | 1982-12-24 | 1984-07-09 | Fujisawa Pharmaceut Co Ltd | ピペラジン誘導体 |
JPS59199679A (ja) * | 1983-04-27 | 1984-11-12 | Kanebo Ltd | 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物 |
EP0189473B1 (de) * | 1984-08-15 | 1992-05-27 | Schering Aktiengesellschaft | Neue dopamin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4554287A (en) * | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones |
US4772705A (en) * | 1985-07-25 | 1988-09-20 | Pennwalt Corporation | Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines |
MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
FR2665161B1 (fr) * | 1990-07-26 | 1992-11-27 | Esteve Labor Dr | Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments. |
US5681954A (en) * | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
DE69635135T2 (de) | 1995-12-28 | 2006-07-06 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazolderivate |
USH2007H1 (en) * | 1996-01-19 | 2001-12-04 | Fmc Corporation | Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines |
TW453999B (en) | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
DE69929689T2 (de) * | 1998-05-22 | 2006-11-02 | Scios Inc., Fremont | Heterocyclische Verbindungen und Verfahren zur Behandlung von Herzversagen und anderer Erkrankungen |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
CA2548657A1 (en) * | 2003-12-18 | 2005-06-30 | Tibotec Pharmaceuticals Ltd. | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
PL1711485T3 (pl) * | 2003-12-18 | 2009-11-30 | Tibotec Pharm Ltd | Pochodne aminobenzoimidazoli jako inhibitory replikacji wirusa zespólni układu oddechowego |
US7557108B2 (en) * | 2007-02-07 | 2009-07-07 | Hoffmann-La Roche Inc. | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2709169A (en) * | 1955-05-24 | X c chs | ||
GB971043A (en) * | 1960-05-18 | 1964-09-30 | May & Baker Ltd | New phenylpiperazine compounds |
FR1410958A (fr) * | 1960-05-18 | 1965-09-17 | May & Baker Ltd | Nouvelles nu-phényl pipérazines et leur procédé de préparation |
US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
US3491098A (en) * | 1967-05-29 | 1970-01-20 | Sterling Drug Inc | 1-((imidazolyl)-lower-alkyl)-4-substituted-piperazines |
-
1978
- 1978-01-04 US US05/866,882 patent/US4179505A/en not_active Expired - Lifetime
- 1978-02-23 PH PH20813A patent/PH16204A/en unknown
- 1978-03-08 CA CA000298497A patent/CA1119597A/en not_active Expired
- 1978-03-16 FR FR7807675A patent/FR2385713A1/fr active Granted
- 1978-03-16 SE SE7803057A patent/SE7803057L/xx unknown
- 1978-03-20 ES ES468077A patent/ES468077A1/es not_active Expired
- 1978-03-20 AU AU34313/78A patent/AU517661B2/en not_active Expired
- 1978-03-22 GB GB11524/78A patent/GB1598278A/en not_active Expired
- 1978-03-28 IT IT48628/78A patent/IT1103464B/it active
- 1978-03-28 LU LU79326A patent/LU79326A1/xx unknown
- 1978-03-28 GR GR55810A patent/GR66124B/el unknown
- 1978-03-28 DK DK135878A patent/DK135878A/da unknown
- 1978-03-28 IL IL7854373A patent/IL54373A/xx unknown
- 1978-03-29 NO NO781078A patent/NO781078L/no unknown
- 1978-03-29 FI FI780954A patent/FI780954A/fi not_active Application Discontinuation
- 1978-03-29 PL PL1978205650A patent/PL118310B1/pl unknown
- 1978-03-29 AT AT0220978A patent/AT368136B/de not_active IP Right Cessation
- 1978-03-29 JP JP3536678A patent/JPS53141287A/ja active Granted
- 1978-03-29 SU SU782595004A patent/SU986297A3/ru active
- 1978-03-29 NL NL7803312A patent/NL7803312A/xx not_active Application Discontinuation
- 1978-03-29 DE DE19782813523 patent/DE2813523A1/de not_active Ceased
- 1978-03-29 IE IE608/78A patent/IE46507B1/en unknown
- 1978-03-30 HU HU78JA815A patent/HU180477B/hu unknown
- 1978-03-30 PT PT67855A patent/PT67855B/pt unknown
- 1978-03-30 NZ NZ186836A patent/NZ186836A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JPS6339591B2 (el) | 1988-08-05 |
IL54373A (en) | 1982-03-31 |
DE2813523A1 (de) | 1978-10-05 |
ES468077A1 (es) | 1979-09-01 |
NZ186836A (en) | 1981-03-16 |
LU79326A1 (fr) | 1978-06-29 |
IL54373A0 (en) | 1978-06-15 |
PT67855A (en) | 1978-04-01 |
PL118310B1 (en) | 1981-09-30 |
ATA220978A (de) | 1982-01-15 |
JPS53141287A (en) | 1978-12-08 |
AU3431378A (en) | 1979-09-27 |
IT1103464B (it) | 1985-10-14 |
IT7848628A0 (it) | 1978-03-28 |
PL205650A1 (pl) | 1979-04-09 |
AT368136B (de) | 1982-09-10 |
SE7803057L (sv) | 1978-10-01 |
AU517661B2 (en) | 1981-08-20 |
DK135878A (da) | 1978-10-01 |
PT67855B (en) | 1980-03-04 |
IE46507B1 (en) | 1983-06-29 |
SU986297A3 (ru) | 1982-12-30 |
IE780608L (en) | 1978-09-30 |
CA1119597A (en) | 1982-03-09 |
FR2385713A1 (fr) | 1978-10-27 |
FI780954A (fi) | 1978-10-01 |
HU180477B (en) | 1983-03-28 |
US4179505A (en) | 1979-12-18 |
NL7803312A (nl) | 1978-10-03 |
PH16204A (en) | 1983-08-02 |
GB1598278A (en) | 1981-09-16 |
GR66124B (el) | 1981-01-16 |
FR2385713B1 (el) | 1983-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO781078L (no) | 5-(4-(diarylmetyl)-1-piperazinylalkyl)benzimidazolderivater | |
US4243806A (en) | 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives | |
US7030139B2 (en) | Compounds | |
NO146774B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazin- og piperidinderivater | |
Zhu et al. | N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: design, synthesis and biological evaluation | |
Husain et al. | Benzimidazole: A valuable insight into the Recent Advances and Biological Activities | |
NO301929B1 (no) | 4-aryl-tiazol- eller -imidazol-derivater | |
Liu et al. | Stereoselective synthesis of desloratadine derivatives as antagonist of histamine | |
JPH01228986A (ja) | [(5(6)(1h―アゾール―1―イルメチル)ベンズイミダゾール]カーバメート | |
DE3442860A1 (de) | 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3- on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
DE2737630C2 (el) | ||
NO744530L (el) | ||
AU2022205221A1 (en) | Diarylureas As CB1 Allosteric Modulators | |
NO831642L (no) | Kinazolinderivater. | |
Deepak et al. | Review on: benzimidazole derivatives as potent biological agent | |
BE865110A (nl) | Nieuwe 5- (4-(diarylmethyl)-1-piperazinylalkyl) benzimidazoolderivaten, alsmede therapeutische preparaten, die dergelijke derivaten bevatten | |
KR810001715B1 (ko) | 5-[4-(디아릴메틸)-1-피페라지닐알킬〕벤즈이미다졸 유도체의 제조방법 | |
Kuznetsov et al. | Efficient route to benzo [4, 5] imidazo [2, 1-a] phthalazines | |
EP1220844B1 (de) | Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren | |
JPS59225186A (ja) | 新規なグアニジノチアゾ−ル誘導体及びその製造方法 | |
KWUKWANGNOH | SYNTHESIS AND CHARACTERIZATION OF A SUBSTITUTED MANNICH BASE OF BENZIMIDAZOLE DERIVATIVE | |
Verma et al. | International Journal of Modern Pharmaceutical Research | |
DD237509A5 (de) | Verfahren zur herstellung von 2-(1h)-chinolonen | |
DE19945787A1 (de) | Arylsulfonamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
EP1054003A1 (en) | Urocanic acid derivatives |